Clinical Study
Immunosuppression Adversely Affects TST but Not IGRAs in Patients with Psoriasis or Inflammatory Musculoskeletal Diseases
Table 3
The univariate analysis of the TB risk factors with a positive outcome of the Ly-TbSpot test.
| | Variable | All patients () | Ly-TbSpot
| Odds ratio | Significance | | Positive (29.6) | (95% CI) | < |
| | Age, mean (test neg. mean) | 57.5 | 56.8 (59.4) | 1.0 (0.98–1.05) | 0.4 | | Sex, female, (%) | 65 (59.6) | 12 (41.4) | 0.4 (0.1–0.9) | 0.02 | | BCG vaccination, (%) | 46 (42.2) | 8 (27.6) | 0.4 (0.2–1.1) | 0.09 |
| | Born in TB-endemic country, (%) | 12 (11.0) | 6 (20.7) | 3.3 (0.9–12.0) | 0.07 | | Contact with TB, (%) | 15 (13.8) | 5 (17.2) | 1.4 (0.4–4.6) | 0.6 | | Previous TB-history, (%) | 12 (11.0) | 5 (17.2) | 2.2 (0.6–7.8) | 0.2 | | Any risk factor for LTBI, (%) | 33 (30.3) | 14 (48.3) | 2.9 (1.1–7.1) | 0.03 |
| | Positive chest X-ray, (%) | 8 (7.3) | 1 (4.0) | 0.5 (0.1–4.4) | 0.5 |
| | Group 1, (%) | 21 (19.3) | 4 (25.0) | 0.8 (0.2–2.6) | 0.7 | | Group 2, (%) | 71 (65.1) | 22 (31.9) | 1.2 (0.7–2.0) | 0.4 | | Group 3, (%) | 17 (15.6) | 3 (23.1) | 0.8 (0.5–1.2) | 0.3 |
| | Corticosteroids, (%) | 38 (34.9) | 11 (37.9) | 1.0 (0.4–2.5) | 1.0 | | Cytostatic treatment, (%) | 48 (44.0) | 14 (48.3) | 1.1 (0.5–2.6) | 0.9 | | Biological treatment, (%) | 6 (5.5) | 1 (3.4) | 0.5 (0.1–4.1) | 0.5 |
|
|
